Because of its function and restricted expression, PDE10A has been considered a potential therapeutic target for various basal ganglia disorders.[18, 19, 20, 21] We therefore hypothesized that dysregulation of PDE10A may also play a role in the pathology of FOXP1 syndrome. Here, PDE10A is linked to basal ganglia disorder.